- STOCKHOLM, Sweden, September 15, 2015 /PRNewswire/ --
Results presented today at the European Association for the Study of Diabetes (EASD) showed that increased awareness about how patients' and physicians' perceptions of control differ, could benefit physician-patient communication and improve diabetes management.[ 1 ] New findings from the Perceptions of Control (POC) study showed adults with type 2 diabetes uncontrolled on basal insulin had a broader definition of control, perceived greater obstacles to maintaining control and that life was impacted significantly more than physicians expected.[ 1 ]
To view the Multimedia News Release, please click:
"There is a significant gap in perceptions of control between physicians and patients in how they define control, the obstacles and how being uncontrolled on basal insulin impacts patients' daily lives," said Meryl Brod, PhD, lead investigator of the POC research study. "Having a more open dialogue during consultations may provide more insight into these critical factors which could improve diabetes management and lead to more effective individualised treatment plans."
The study identified that physicians defined control in measurable, clinical terms such as frequency/severity of hypoglycaemia (93% vs 69%, p
People with type 2 diabetes uncontrolled on basal insulin perceived more obstacles to achieving control compared to physicians, including stress (75% vs 54%, p
The impact of being uncontrolled on basal insulin and how it interfered in one's life was perceived as significantly greater than physicians believed including aspects such as mood/emotions (63% vs 33%, p
About the Perception of Control(POC)Study
The POC study was based on information collected from a web survey of 300 physicians and 1,012 adults with type 2 diabetes uncontrolled on basal insulin (physician-confirmed HbA1c> 8% (64 mmol/mol)) from the UK (n=100 physicians and 620 patients), Sweden (n=100 physicians and 240 patients) and Switzerland (n=100 physicians and 152 patients).[ 1 ] Information was also collected from a control group of 295 adults with type 2 diabetes controlled on basal insulin (physician-confirmed HbA1c
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com,Facebook,Twitter,LinkedIn,YouTube
Further Information Media: Katrine Sperling +firstname.lastname@example.orgÅsa Josefsson +email@example.comInvestors: Peter Hugreffe Ankersen +45-3075-9085phak@novonordisk.
comMelanie Raouzeos +firstname.lastname@example.orgDaniel Bohsen +email@example.comFrank Daniel Mersebach (US) +firstname.lastname@example.org